Tadasu Matsuo, head of alternative investments at Japan Post Insurance (JPI), has joined HarbourVest Partners as a managing director where he will co-lead Japan coverage alongside Tatsuya Kubo.
Matsuo (pictured) was recruited by JPI in September 2016 to launch the firm’s alternative investment program. He previously spent 14 years at Daido Life Insurance as general manager for alternative investment...
Increased climate change awareness on a corporate level is leading to more investment – either direct or through funds – in start-ups that offer mitigation solutions. Asia is a key geography
Healthcare-focused Panacea Venture has led a $40 million Series C round for China’s XWPharma, a neurobiology-focused biotech developer previously known as XW Laboratories.
Kyee Technology, a Chinese digital medical platform has raised RMB430 million ($64 million) in a Series D round led by Tencent Holdings. Other investors include Longmen Capital, Dyee Capital and Royal Sea Capital.
Biocytogen, a Chinese contract research organization (CRO) that provides genetically-modified mice for drug testing, has raised RMB970 million ($143 million) in an extended tranche of Series D funding.